Business Wire

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid

Share

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies.

H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities.

Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mass will make it a leading content production hub in continental Europe.”

Esteban Caja Samboal, Principal at H.I.G. Europe Realty Partners in Madrid, added: “This transaction further demonstrates our ability to leverage our strong local network, execution capabilities and invest in an innovative real estate asset class leveraging on H.I.G.’s real estate as well as TMT expertise.”

About H.I.G. Capital

H.I.G. is a leading global private equity and alternative assets investment firm with $43 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Rio de Janeiro, São Paulo and Bogotá, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/value-added approach:

  1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
  2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
  3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.

* Based on total capital commitments managed by H.I.G. Capital and affiliates.

Contact information

Riccardo Dallolio
Managing Director
rdallolio@higrealty.com

H.I.G. Capital
P +44 (0) 207 318 5700
F +44 (0) 207 318 5749
www.higcapital.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-198.3.2021 16:53:00 CETPress release

Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics (PTx), is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection. PTx recently announced that a clinical trial of Leukine® conducted in Belgium of hospitalized COVID-19 patients suffering from acute hypoxic respiratory failure requiring supplemental oxygen met the primary endpoint of significant improvement in lung function. Improvement in oxygenation of at least 33% or more from baseline was seen in 54% of patients on the LEUKINE® plus standard-of-care (SOC) arm versus 26% of patients on SOC (p=.0147). Tanner provides a regulatory-compliant pathway to make LEUKINE® available in international markets. If a pat

H.I.G. Capital Expands European WhiteHorse Team with the Addition of Laurent Vaille and Charles Bourgeois8.3.2021 16:30:00 CETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce the expansion of its European WhiteHorse team with the addition of Laurent Vaille and Charles Bourgeois as Principals. Laurent will be based in H.I.G.’s London office, and Charles is based in H.I.G.’s Paris office. Laurent has 13 years of experience in direct lending and corporate finance. He was previously an Executive Director in the Private Debt division of Tikehau Capital in Paris. Prior to that, he worked for Ernst & Young and Deloitte Finance. Charles has 13 years of experience in direct lending and corporate finance. Prior to joining H.I.G., he was an Executive Director in the Private Debt division of Tikehau Capital in Paris. He was previously with GE Capital in the leveraged finance division, after working at SG and LD&A Jupiter. Commenting on the hire, Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said, “Hiring profe

PerkinElmer Adds HPLC Columns to Consumables Portfolio8.3.2021 16:22:00 CETPress release

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it has added state-of-the-art columns and chemistries to its LC consumables portfolio by acquiring ES Industries, based in West Berlin, New Jersey in the U.S. ES Industries is known for its innovative and highly efficient HPLC and supercritical fluid chromatography (SFC) column chemistries. The team has over 40 years of experience delivering columns with superior reliability, scalability, and reproducibility that are used routinely for method development processes, LC/MS analysis, quality control and preparative purification. Building on PerkinElmer’s https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.perkinelmer.com%2Fcategory%2Fliquid-chromatography-hplc-uhplc-instruments&esheet=52392346&newsitemid=20210308005611&lan=en-US&anchor=recently+announced+LC+300TM+HPLC%2FUHPLC+and+SimplicityChromTM+CDS+solution&index=3&md5=8aaa6199b7c1a347615a2b8ae0dd87b1 recently announ

Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry During the Week of Rare Disease Day 20218.3.2021 15:25:00 CETPress release

Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare disease product received FDA approval on Friday, 26 February 2021, during the week when the world celebrated #RareDiseaseDay2021. Veristat’s biostatisticians, programmers, and medical writers collaborated with Origin Biosciences to support the New Drug Application (NDA) for Nulibry. The entire Veristat team is honored to know that the hard work and perseverance of the combined Origin/Veristat team brought new hope for children whose lives are shortened by the devastating disease MoCD Type A. “We thank the entire Veristat team who worked diligently to help us bring this critical therapy to patients with no other FDA-approved treatment options,” said Dr. Liza Squires, Origin Chief Medical

CBS News “Global Thought Leaders” Series Features Echosens: Video Showcases FibroScan ® as Medical Gold Standard8.3.2021 15:01:00 CETPress release

Echosens, a high-technology company offering the FibroScan® family of products, is pleased to announce that it has been chosen for the “Global Thought Leaders” series broadcast on CBS News. View a short video highlighting the Company’s groundbreaking work in the development of vital medical resources, including FibroScan®, a noninvasive solution for measuring liver elasticity and fat content of the liver at the point of care. “We’re pleased to be selected by CBS News and proud of the video created at our international headquarters in Paris which captures the essence of Echosens, including interviews with some of our top leaders and a clinician performing a FibroScan® exam with her patient,” says Dominique Legros, Group CEO, Echosens. “Reliable, accurate and affordable, FibroScan® is designed to address a growing liver disease epidemic. Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the worldwide population and as many as 6% are affected by NASH, which is expected

Infor and C3 AI Form Strategic Partnership to Deliver Scalable Enterprise AI Industry Applications8.3.2021 15:00:00 CETPress release

C3 AI (NYSE: AI), a leading enterprise AI software provider, and Infor, an ERP technology cloud leader, today announced a wide-ranging strategic alliance designed to jointly expand enterprise-class artificial intelligence (AI) solutions across applicable industries to extend Infor’s native machine learning capabilities. This will allow Infor to explore expansion of its industry offerings into edge scenarios and analyze ways to provide deeper capabilities beyond standard Infor offerings. Infor plans to market, license, and deploy C3 AI prebuilt solutions to Infor customers under the Infor brand and to explore new solutions using the C3 AI® Suite. Infor and C3 AI expect to leverage both companies’ existing digital portfolios to collaborate on new integrated enterprise AI applications that can support specific industry needs. The initial focus will be on predictive maintenance surrounding Internet of Things (IoT) systems with the goal of providing a more proactive and accurate maintenance

Zynga Teams up with Girls Who Code to Help Raise Awareness and Support for Women in Tech8.3.2021 15:00:00 CETPress release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced that it has teamed up with Girls Who Code in support of International Women’s Day 2021. With a mission to raise awareness and support for women in tech, Zynga has pledged $100,000 from its Social Impact Fund to enable Girls Who Code (GWC) to support girls at all points throughout their educational journey from 3rd grade into the workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005082/en/ Zynga Teams up with Girls Who Code to Help Raise Awareness and Support for Women in Tech (Graphic: Business Wire) GWC is an international non-profit organization dedicated to closing the gender gap in technology. The organization has reached more than 300,000 girls in the US, Canada, UK, and India; 50 percent of girls served are Black, Latinx, or from low-income backgrounds. Through its free Clubs program, GWC reaches young women at the mo